KUALA LUMPUR: Pharmaniaga Bhd
sustained its recovery momentum on the back of higher demand from government hospitals, sustained momentum within the manufacturing division, as well as lower finance costs arising from partial repayment of borrowings supported by effective inventory management.
In the first quarter ended March 31, 2026, the group posted a net profit of RM31.47mil, as compared to RM29.58mil in the year-ag quarter. Earnings per share rose to 0.48 sen from 2.05 sen in the comparative quarter.
Quarterly revenue rose to RM1.18bil from RM1.06bil in the previous comparative quarter.
According to the group, its manufacturing division continued to record encouraging progress during the quarter, encouraged by stronger demand for in-house manufactured products and improved operational performance across our facilities.
The logistics and distribution business registered higher order volumes under the expanded approved product price list, while the Indonesia operations maintained steady momentum, driven by stronger contributions from existing principals
"We are also making steady progress in expanding both our biopharmaceutical and pharmaceutical portfolios. This includes advancements in human insulin and vaccine development, alongside the introduction of products in key therapeutic areas such as cardiovascular, urology and metabolic treatments.
"The planned launch of a new anti-diabetic product range in the coming quarter is expected to further strengthen our portfolio and support our expansion within the private healthcare segment,” said managing director Datuk Zulkifli Jafar in a statement.
He noted no direct disruption to medicine supply with the public health system from the ongoing geopolitical and cost pressures arising from developments in the Middle East.
"The group’s inventory position remains stable, supported by sufficient buffer stock levels to meet current demand nationwide.
“Nevertheless, we will remain cautious and vigilant as well as continue to work closely with the Government and relevant stakeholders to ensure the resilience, efficiency and reliability of the national healthcare supply chain."
